ALK Abelló A/S : Save the date for ALK's Capital Markets Day on 4 June 2024
March 26, 2024 at 06:34 pm IST
Share
English
Published: 2024-03-26 14:00:00 CET
ALK-Abelló
Investor News
Save the date for ALK's Capital Markets Day on 4 June 2024
ALK (ALKB:DC / OMX: ALK B / AKBLF) will host a Capital Markets Day on 4 June 2024 in the afternoon at the company's headquarters in Hørsholm, Denmark.
At the Capital Markets Day, the Board of Management will elaborate on the results of the current strategy review.
An invitation will be sent out closer to the event.
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434
About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,700 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.
Attachment
ALK 26032024_Investor News_UK_CMD_Save the date
Attachments:
ALK 26032024_Investor News_UK_CMD_Save the date.pdf
This news release was distributed by Company News System, www.nasdaqomxnordic.com/news/marketnotices
To subscribe on regulatory news from this company, go to the subscription page
Attachments
Original Link
Permalink
Disclaimer
ALK-Abelló A/S published this content on
26 March 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
26 March 2024 13:03:06 UTC.
ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Companyâs allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.